Rating- neutral; Pharma sector- Poised for strong growth in Q1FY24
时间:2024-06-26 12:53:56 阅读(143)
We anticipate a positive performance from our pharmaceutical sector coverage in Q1FY24, driven by improved sales in the US market and strong performance across most branded markets. As the cost pressures gradually ease, we expect to see a robust y-o-y Ebitda growth of 22% (excluding BIOS and Mankind). In the hospital segment, we project a relatively stable performance compared to the previous quarter, with occupancy trends gradually returning to pre-Covid levels. For diagnostic companies, we anticipate a slight increase in non-Covid realisations per patient on a quarterly basis, supported by price hikes and higher volumes of non-Covid tests. Our top picks in the pharma sector are Sun Pharma (SUNP), Mankind, and Cipla. Although recent price increases may limit short-term upside, we maintain a positive outlook on APHS, Rainbow, and KIMS in the healthcare services sector.
Pharma: Improved US, healthy branded markets, yoy margin expansion in store
Hospitals: Steady quarter in store We expect a sequentially steady performance for the India-based hospitals, with lower occupancies being offset by higher ARPOB. For hospitals, we forecast a topline growth of 15% y-o-y in Q1FY24. Overall, we expect an Ebitda growth of 20% y-o-y for our hospitals.
Diagnostics: We expect an uptick in B2C sales growth
Regarding the diagnostic firms, we anticipate a slight increase in non-Covid revenue per patient q-o-q, supported by price adjustments and higher volumes of non-Covid tests. We have factored in a y-o-y growth of 8-12% in non-Covid sales for DLPL and METROHL. We expect a decrease in Covid-related sales for both compared to the last quarter. In Q1FY24, we project a 20% q-o-q Ebitda growth rate for DLPL and a 2% q-o-q growth rate for METROHL. The lower growth rate for METROHL is due to the loss of the NACO contract, which accounted for 4-5% of sales, starting from February 2023.
上一篇:BJP MLA Ramdular Gond disqualified from UP assembly after conviction in rape case
下一篇:Wipro’s Q2 results place stock under pressure- Should you buy, hold or sell the stock-
猜你喜欢
- Blue Jet Healthcare lists at 10% premium on bourses; Should you hold or book profit-
- Tis the season for…holiday blues! How to stay calm & stress-free – Top tips by a psychologist
- Gloves are off on Taiwan’s Elections- How China is Influencing the Democratic Process
- Bharat Jodo Nyay Yatra- Focus in UP on areas that Rahul Gandhi’s first rally did not cover
- This Rakesh Jhunjhunwala bank stock rallies 9% YTD; analysts see up to 34% upside, check target price
- Bids invited for city-gas in J&K, Ladak and northeast
- Global Markets- Oil surge fans inflation fears, dampens stocks
- Buy HUDCO, Syngene International to pocket short-term gains; Nifty must hold above 18,200 for upmove
- Global Markets- Stocks steadier as real bond yields back off